Express Pharma
Home  »  Latest Updates  »  Quest Life Sciences acquires assets of FCRL

Quest Life Sciences acquires assets of FCRL

34
Read Article

Quest will move the entire facility to Kandla, Gujarat in the special economic zone where it will set up a state-of-the-art BA/BE centre

Quest Life Sciences, Chennai one of the fast growing CRO in India, acquired the entire assets of Fortis Clinical Research Ltd (FCRL). Quest is moving the entire facility to Kandla, Gujarat in the special economic zone where Quest will set up a state-of-the-art BA/BE centre, which is likely to be commissioned by June, 2015.

TS Jaishankar, Managing Director, Quest Life Sciences, Chennai informed that their present capacity in Chennai is almost fully utilised and the Kandla venture has been primarily initiated because of the speed and single window clearance of the Gujarat Govt. Quest Life Sciences have been audited five times by the US FDA besides MHRA UK, Spanish Govt, AEMPS, MOH Malaysia, etc.

The construction is nearing completion and hence FCRL acquisition has been at the most opportune time. Quest has offices in New Jersy, US, Moscow and Bangkok; besides Kandla and Chennai.

Comments are closed.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Want to know more about "Omic's" and it's relevance?
Register Now
close-image